A Randomized Double-blind Placebo controlled Multi-center 2-part Phase 2 Study to Evaluate Efficacy Safety and Tolerability of RGH-706 in Prader-Willi Syndrome

Brief description of study

A Randomized, Double-blind Placebo controlled, Multi-center, 2-part, Phase 2 Study to Evaluate Efficacy, Safety, and Tolerability of RGH-706 in Prader-Willi Syndrome


Clinical Study Identifier: s22-00255
ClinicalTrials.gov Identifier: NCT05322096
Principal Investigator: Jorge Mejia-Corletto.


If you are registered as a volunteer, please log in to contact the study team/express interest in this study.

Contact the research team to learn more about this study.

By clicking "Contact Research Team", your contact information will be sent securely to the research staff associated with the study. You will also receive a copy of this email in your inbox, as well as other notifications to determine your participation status in the study.